Haris Ali, MD, City of Hope

Novel agents in the pipeline for the treatment of acute and chronic GVHD are discussed.

A review of treatment options for patients with chronic GVHD who don’t respond to steroid therapy and preliminary findings from the phase 3 REACH3 trial.

Defining steroid-refractory acute GVHD, treatment options for patients who don’t respond to steroid therapy, and a review of the REACH2 trial.

Experts in hematology-oncology share insights on approaching initial treatment and the treatment goals for acute and chronic GVHD.

A discussion on the role of prophylactic therapy for patients after transplant as well as available options for GVHD prophylaxis.

Hematologist-oncologists review the typical presentation and diagnosis of acute and chronic GVHD and define how severity is classified.

Corey S. Cutler, MD, MPH, FRCPC; Yi-Bin Chen, MD; and Haris Ali, MD, provide insight on the nature of graft-vs-host disease (GVHD) and common risk factors for acute and chronic GVHD.